Zandelisib Displays "Exemplary" Efficacy in Relapsed/Refract

Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.

Related Keywords

Poland , Wojciech Jurczak , Astrazeneca ,